NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
5/8 — Partial
RYTARY (carbidopa and levodopa) by Viatris is dopa decarboxylase inhibitors [moa]. First approved in 2015.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYTARY is an extended-release oral capsule combining carbidopa (a decarboxylase inhibitor) and levodopa, a dopamine precursor used to treat Parkinson's disease motor symptoms. The formulation enables prolonged therapeutic dopamine levels in the brain by slowing levodopa metabolism. It targets patients with advanced Parkinson's disease seeking symptom control beyond immediate-release formulations.
$267MPart D
LOE Approaching2.3 years to LOEProduct is in late-stage life cycle with 2.3 years of patent protection remaining; commercial teams are pivoting toward LOE mitigation and defensive strategies.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Why This Matters for Your Career
Worked on RYTARY at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.